Valink Therapeutics

Develops bispecific antibody-drug conjugate cancer candidates and offers collaboration on its discovery platform to biopharma partners

London, United KingdomFounded 2020valinktherapeutics.comWebsite technologies

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-11-13

About Valink Therapeutics

Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for cancer, designed to attack tumour cells more selectively while sparing healthy tissue. Its proprietary LiliumX discovery platform combines synthetic protein biology, high-throughput functional screening and AI, and its V-Gate approach tunes binding to continuous levels of two cell-surface targets.

The company advances three oncology-focused programs and invites collaboration on its discovery engine. It closed an $11.8 million pre-A financing round in October 2025 and announced a strategic alliance with Nona Biosciences in December 2025.

Valink was founded in 2020 and is headquartered in London, United Kingdom, at Imperial I-Hub. It also lists an office in Cambridge, Massachusetts, United States. Its leadership includes co-founders Arne Scheu (CEO) and Irsyad Khairil (CTO), and its board is chaired by Martin D. Williams.

Product: Bispecific antibody-drug conjugate drug candidates for oncology, discovered with the LiliumX platform and V-Gate approach.

Jobs at Valink Therapeutics

No open positions listed right now.

Leadership

More biotech & pharma companies

  • Valneva UK

    Develops and supplies travel vaccines and clinic support for healthcare providers
    London, United KingdomBiotech & pharmaFounded 2015
  • Vector Futures

    AI-guided genetic engineering and contract research for biological product developers
    London, United KingdomBiotech & pharmaFounded 2024
    Young companyNew on Evolc
  • Vedaly

    AI research platform and data consulting for biopharma R&D and translational teams
    Cambridge, United KingdomBiotech & pharmaFounded 2024
    Young companyNew on Evolc
  • Verdiva Bio

    Develops once-weekly peptide medicines for obesity and cardiometabolic disease, with a lead drug in Phase 2 trials
    London, United KingdomBiotech & pharmaFounded 2024
    Young company
  • Vernalis (R&D)

    Drug discovery research and development services for pharmaceutical and biotechnology partners
    Cambridge, United KingdomBiotech & pharmaFounded 1986
  • Viramal

    Develops women's health medicines and therapies for sexual, vaginal and reproductive conditions
    London, United KingdomBiotech & pharmaFounded 2013
    New on Evolc

All biotech & pharma companies →

Website technologies

Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.

Content delivery

Content management

  • WebflowHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Hosting

  • AWSHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.